Novus Biologicals products are now on bio-techne.com

Recombinant Human VEGF 165b Protein

Images

 
There are currently no images for VEGF (3045-VE).

Every product we sell is backed by Novus' 100% Guarantee. If you have used this product, please submit your images and reviews to earn reward points.

Product Details

Summary
Reactivity HuSpecies Glossary
Applications Bioactivity

Order Details

View Available Formulations
Catalog# & Formulation Size Price
Novus Biologicals is part of Bio-Techne

Shop this product on bio-techne.com

Recombinant Human VEGF 165b Protein Summary

Details of Functionality
Measured by its binding ability in a functional ELISA. Serially diluted Recombinant Human (rh) VEGF165b is added to a Recombinant Human VEGF R2/KDR/Flk‑1 Fc Chimera (Catalog # 357-KD) coated plate (2 μg/mL, 100 μL/well). Bound rhVEGF165b is detected by a human VEGF165b specific antibody (Catalog # MAB3045). The concentration of rhVEGF165b that produces half-maximum response is approximately 0.12-0.6 nM.
Source
Spodoptera frugiperda, Sf 21 (stably transfected)-derived human VEGF protein
Ala27-Asp191
Accession #
N-terminal Sequence
Ala27
Structure / Form
Disulfide-linked homodimer
Protein/Peptide Type
Recombinant Proteins
Gene
VEGFA
Purity
>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
Endotoxin Note
<0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

Dilutions
  • Bioactivity
Theoretical MW
19.1 kDa (monomer).
Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
SDS-PAGE
19-24 kDa, reducing conditions
Publications
Read Publications using
3045-VE in the following applications:

Packaging, Storage & Formulations

Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
Buffer
Lyophilized from a 0.2 μm filtered solution in PBS with BSA as a carrier protein.
Purity
>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
Reconstitution Instructions
Reconstitute at 100 μg/mL in PBS containing at least 0.1% human or bovine serum albumin.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human VEGF 165b Protein

  • MVCD1
  • VAS
  • vascular endothelial growth factor A
  • Vascular permeability factor
  • Vasculotropin
  • VEGF
  • VEGFA
  • VEGF-A
  • VEGFMGC70609
  • VPF
  • VPFvascular endothelial growth factor

Background

Vascular endothelial growth factor (VEGF or VEGF-A), also known as vascular permeability factor (VPF), is a potent mediator of both angiogenesis and vasculogenesis in the fetus and adult (1-3). It is a member of the PDGF family that is characterized by the presence of eight conserved cysteine residues and a cystine knot structure (4). Humans express two sets of alternately spliced isoforms of 121, 145, 165, 183, 189, and 206 amino acids (aa) in length (4). VEGF165 appears to be the most abundant and potent of the angiogenic isoform set, followed by VEGF121 and VEGF189 (3, 4). The anti-angiogenic or “b” set of isoforms is differentially spliced to contain six alternate amino acids at the C-terminus, and are the more highly expressed isoforms in normal adult tissue (5). VEGF165b, like VEGF121 but unlike most angiogenic isoforms, does not bind heparins and is therefore diffusible (4, 6). Human VEGF165b shares 88% aa sequence identity with corresponding regions of mouse and rat, 96% with porcine, 95% with canine, and 93% with feline, equine and bovine VEGF165b, respectively. VEGFs bind the type I transmembrane receptor tyrosine kinases VEGF R1 (also called Flt-1) and VEGF R2 (Flk-1/KDR) on endothelial cells (4). Although VEGF affinity is highest for binding to VEGF R1, VEGF R2 appears to be the primary mediator of VEGF angiogenic activity (3, 4). The affinity of VEGF165b for VEGF R2 is similar to that of VEGF165, but VEGF165b only partially activates VEGF R2 such that the kinase regulatory site Y1054 is not phosphorylated (6). VEGF165b also does not bind neuropilin-1, suggesting that the functional difference between VEGF165 and VEGF165b maybe due to either the lack of neuropilin-1 co-signaling or unique downstream signaling activated by VEGF165b (8). Since VEGF165b may compete with angiogenic VEGFs for VEGF R2 sites, its ectopic expression in tumors has been shown to inhibit their growth (7).

  1. Leung, D.W. et al. (1989) Science 246:1306. 
  2. Keck, P.J. et al. (1989) Science 246:1309. 
  3. Byrne, A.M. et al. (2005) J. Cell. Mol. Med. 9:777. 
  4. Robinson, C.J. and S.E. Stringer (2001) J. Cell. Sci. 114:853.
  5. Nowak, D.G. et al. (2008) J. Cell Sci. 121:3487.
  6. Kawamura, H. et al. (2008) Cancer Res. 68:4683.
  7. Rennel, E.S. et al. (2008) Br. J. Cancer 98:1250.
  8. Harper S.J. and Bates D.O. (2008) Nat. Rev. Cancer 8(11):880.

Customers Who Viewed This Item Also Viewed...

233-FB
Species: Hu
Applications: BA
AF321
Species: Hu
Applications: Block, CyTOF-ready, Flow, IHC, WB
AF644
Species: Mu
Applications: CyTOF-ready, Dual ISH-IHC, Flow, IHC, Neut, WB
NB100-105
Species: Bv, Ca, Fe, Ma, Hu, Pm, Mu, Po, Pm, Rb, Rt, Sh, Xp
Applications: ChIP, ChIP, ELISA, Flow, GS, IA, IB, ICC/IF, IHC-FrFl, IHC, IHC-Fr, IHC-P, IP, In vitro, KD, KO, LA, PLA, Simple Western, TCS, WB
M6000B
Species: Mu
Applications: ELISA
923-AN
Species: Hu
Applications: BA
AF3628
Species: Hu, Mu, Rt
Applications: CyTOF-ready, Flow, ICC, IHC, Simple Western, WB
AF231
Species: Hu
Applications: CyTOF-ready, Dual ISH-IHC, ELISA(Cap), ELISA(Det), ELISA(Sta), Flow, ICC, IHC, IP, Simple Western, WB
AF887
Species: Hu, Mu, Rt
Applications: CyTOF-ready, IHC, ICFlow, Simple Western, WB
NB110-41083
Species: Hu
Applications: ChIP, ELISA, ICC/IF, WB
AF4117
Species: Rt
Applications: IHC, WB
DPG00
Species: Hu
Applications: ELISA
NBP2-22203
Species: Hu, Pm, Mu, Rt
Applications: ELISA, Flow, ICC/IF, IHC, IHC-P, WB
AF1230
Species: Hu, Mu, Rt
Applications: IHC, KO, WB
294-HG
Species: Hu
Applications: BA

Publications for VEGF (3045-VE)(6)

We have publications tested in 4 confirmed species: Human, Mouse, Rat, Bovine.

We have publications tested in 3 applications: Bioassay, In Vivo, Western Blot.


Filter By Application
Bioassay
(4)
In Vivo
(1)
Western Blot
(1)
All Applications
Filter By Species
Human
(3)
Mouse
(1)
Rat
(1)
Bovine
(1)
All Species
Showing Publications 1 - 6 of 6.
Publications using 3045-VE Applications Species
F Bucher, E Aguilar, KV Marra, J Rapp, J Arnold, S Diaz-Aguil, C Lange, H Agostini, G Schlunck, A Stahl, M Friedlande CNTF Prevents Development of Outer Retinal Neovascularization Through Upregulation of CxCl10 Invest. Ophthalmol. Vis. Sci., 2020-08-03;61(10):20. 2020-08-03 [PMID: 32780864] (Bioassay, Human, Mouse) Bioassay Human, Mouse
A Boudria, C Abou Fayca, T Jia, S Gout, M Keramidas, C Didier, N Lemaître, S Manet, JL Coll, AC Toffart, D Moro-Sibil, C Albiges-Ri, V Josserand, E Faurobert, C Brambilla, E Brambilla, S Gazzeri, B Eymin VEGF165b, a splice variant of VEGF-A, promotes lung tumor progression and escape from anti-angiogenic therapies through a ?1 integrin/VEGFR autocrine loop Oncogene, 2018-09-07;0(0):. 2018-09-07 [PMID: 30194450] (Bioassay, Human) Bioassay Human
A Jahangiri, A Nguyen, A Chandra, MK Sidorov, G Yagnik, J Rick, SW Han, W Chen, PM Flanigan, D Schneidman, S Mascharak, M De Lay, B Imber, CC Park, K Matsumoto, K Lu, G Bergers, A Sali, WA Weiss, MK Aghi Cross-activating c-Met/?1 integrin complex drives metastasis and invasive resistance in cancer Proc. Natl. Acad. Sci. U.S.A., 2017-09-26;0(0):. 2017-09-26 [PMID: 28973887] (Bioassay, Human) Bioassay Human
HL Deissler, GK Lang, GE Lang Inhibition of Single Routes of Intracellular Signaling is Not Sufficient to Neutralize the Biphasic Disturbance of a Retinal Endothelial Cell Barrier Induced by VEGF-A165 Cell. Physiol. Biochem., 2017-07-18;42(4):1493-1513. 2017-07-18 [PMID: 28719888] (Bioassay, Bovine) Bioassay Bovine
The control of alternative splicing by SRSF1 in myelinated afferents contributes to the development of neuropathic pain Neurobiol Dis, 2016-09-09;96(0):186-200. 2016-09-09 [PMID: 27616424] (In Vivo, Rat) In Vivo Rat
Bates , David O, Mavrou , Athina, Qiu , Yan, Carter , James G, Hamdollah-Zadeh , Maryam, Barratt , Shaney, Gammons , Melissa, Millar , Ann B, Salmon , Andrew H, Oltean , Sebastia, Harper , Steven J Detection of VEGF-A(xxx)b isoforms in human tissues. PLoS ONE, 2013-07-31;8(7):e68399. 2013-07-31 [PMID: 23935865] (Western Blot) Western Blot

Reviews for VEGF (3045-VE) (0)

There are no reviews for VEGF (3045-VE). By submitting a review you will receive an Amazon e-Gift Card or Novus Product Discount.
  • Review with no image -- $10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen
  • Review with an image -- $25/€18/£15/$25 CAD/¥150 Yuan/¥2500 Yen

FAQs for VEGF (3045-VE). (Showing 1 - 1 of 1 FAQs).

  1. Why is the molecular weight of VEGF different from the similar antibody, for some companies the the molecular weight is 40KD)?
    • I can't comment on another company's antibody because I don't have any information about their products. I can tell you that VEGF is expressed in a variety of isoforms and is subject to various post-translational modifications that influence its apparent molecular weight in an SDS-PAGE gel compared to the theoretical molecular weight.

Additional VEGF Products

Blogs on VEGF. Showing 1-10 of 23 blog posts - Show all blog posts.

Unlocking the Potential of Biosimilars in Immuno-Oncology
By Jennifer Jones, M.S.Biosimilar Antibodies: Imitation Meets InnovationIn the ever-evolving medical landscape, a new class of pharmaceuticals is emerging as a game-changer, poised to transform the way we approach...  Read full blog post.

Understanding ‘Y’ in Breast Cancer: Crucial Role of DNA/RNA-binding Protein YB-1 in the Development, Pre-Invasive, and Metastatic Phases
Jamshed Arslan, Pharm D, PhD In the United States, 1 in 8 women will be diagnosed with breast cancer in her lifetime.1 Despite the prevalence, cancer genesis is a mystery. The heterogeneity of cancers makes it diff...  Read full blog post.

Detecting HIF alpha and beyond: Best controls for hypoxia Western blot analysis
By Rosa Moreno, PhD. Detecting HIF alpha and beyond: Best controls for hypoxia Western blot analysisPhysiological low levels of oxygen induce normal hypoxic events across biological systems. This hypoxic state activ...  Read full blog post.

Neurovascular signaling for repair enhances brain metastasis
By Jamshed Arslan, Pharm. D., PhD. Stroke    is a leading cause of mortality and morbidity worldwide. Cellular players – neurons, astrocytes, endothelial and stromal cells – involved in post-stroke repair t...  Read full blog post.

mTOR Signaling and the Tumor Microenvironment
By Yoskaly Lazo-Fernandez, PhD The mammalian target of rapamycin (mTOR) is a conserved serine/threonine kinase that, as a member of two distinct intracellular protein complexes, mTORC1 and mTORC2, regulates protein ...  Read full blog post.

Chemotherapy-induced metastasis: An unexpected foe?
By Yoskaly Lazo-Fernandez, PhD IntroductionEvidence has accumulated recently indicating that common cancer therapies might stimulate metastasis in a significant number of cancer patients1. In fact, neoadjuvant che...  Read full blog post.

Getting Physical: Link between Lipid Metabolism and Hypoxia Target Genes
By Jamshed Arslan Pharm.D. von Hippel-Lindau (VHL) disease is associated with tumors arising in multiple organs. Activation of hypoxia-inducible factor (HIF)-alpha underlies the VHL disease pathogenesis. In normoxia...  Read full blog post.

The role of HIF-2 alpha in the progression and therapy of clear cell renal cell carcinoma
HIF-2 alpha, also known as hypoxia-inducible factor 2, endothelial PAS domain protein-1, and member of PAS superfamily 2 is part of the HIF family of proteins.  The HIF family is composed of HIF-1, HIF-2 and HIF-3, where HIF-2 is a dimeric protein ...  Read full blog post.

The application of CD31/Pecam-1 (MEC 7.46) in breast cancer research
CD31/PECAM-1, or platelet endothelial cell adhesion molecule 1, is a 130-kDa glycoprotein expressed on vascular and hematopoietic cells.  Depending on the cell type, CD31/PECAM-1 expression can be largely localized to cell junctions, playing a rol...  Read full blog post.

The dynamic use of a PCNA antibody in fish, porcine and primate species
Proliferating cell nuclear antigen (PCNA) plays a crucial role in nucleic acid metabolism as it pertains to DNA replication and repair.  Most noted for its activation of subunits of DNA polymerase, it has also been found to interact with cell-cycl...  Read full blog post.

Showing 1-10 of 23 blog posts - Show all blog posts.
Read our latest blog and use the new citation tool on bio-techne.com

Customers Who Bought This Also Bought

Contact Information

Product PDFs

Calculators

Concentration Calculator

The concentration calculator allows you to quickly calculate the volume, mass or concentration of your vial. Simply enter your mass, volume, or concentration values for your reagent and the calculator will determine the rest.

=
÷

Review this Product

Be the first to review our Recombinant Human VEGF 165b Protein and receive a gift card or discount.

Bioinformatics

Gene Symbol VEGFA
Uniprot